Introduction {#sec1}
============

Over the past decade, implant therapy has been widely accepted and chosen as a routine procedure for the reconstruction of fully or partially edentulous individuals. However, peri-implantitis has been shown to affect long-term success following the osseointegration process and the stability of the established implants \[[@B1]\].

Peri-implantitis is defined as an inflammatory response surrounding implants and is characterized by an infection of the soft tissue and loss of the surrounding bone \[[@B2]\]. The host immune defense against bacterial challenge is responsible for the peri-implant tissue damage \[[@B3]\]. Lymphocytes, macrophages, and neutrophils are recruited and activated by the immune system and induce a local inflammatory response in the soft and bone tissues by producing cytokines and chemokines \[[@B4]\]. In particular, proinflammatory cytokines (e.g. TNF-α, IFN-γ, IL-1β, IL-6, IL-12, IL-17, and receptor activator of nuclear factor κB (NF-κB) ligand (RANKL)), anti-inflammatory cytokines (e.g. IL-4 and IL-10) and chemokines (e.g. IL-8, monocyte chemoattractant protein-1, and macrophage inflammatory protein-1α) have been suggested to be important mediators of inflammation and immunity during the pathogenesis of peri-implantitis \[[@B5]--[@B9]\]. Additionally, this local immune-inflammatory process is associated with disrupted bone remodeling. Osteoclastogenesis induction appears to be a major determinant of the uncoupling of bone resorption and bone formation, resulting in loss of the supporting alveolar bone and, subsequently, implant failure \[[@B10]\].

miRNAs are small non-coding RNA molecules that are approximately 18--22 nts long. These single-stranded molecules regulate gene expression by binding to the complementary sequences in the 3′-untranslated or coding region of the target mRNAs, leading to either blockade of translation or induction of target mRNA degradation \[[@B11],[@B12]\]. Therefore, miRNAs participate in not only physiological processes within cells and tissues but also pathological processes. According to previous reports, miRNAs are specifically involved in many inflammatory and bone-related diseases, such as rheumatoid arthritis, osteoporosis, and periodontitis \[[@B13]--[@B15]\]. Several studies \[[@B15]--[@B17]\] have compared the miRNA profiles of patients with periodontitis with healthy patients, but no reports related to the miRNA profiles of patients with peri-implantitis have been published. Although the two diseases share many features, the results for periodontitis are not necessarily applicable to peri-implantitis. In fact, based on emerging evidence, peri-implantitis and periodontitis exhibit several key differences, including their histopathological and molecular characteristics \[[@B4],[@B18]\]. Considering the aforementioned analysis, inflammatory miRNAs may be differentially expressed in peri-implantitis tissue compared with healthy gingival tissue.

Therefore, in the present study, we used miRNA sequencing to identify differentially expressed miRNAs in canine experimental peri-implantitis and validated the results using real-time PCR. Additionally, we ultimately determined the roles of the miRNAs in this inflammatory process by analyzing the functions of their target genes and identifying the involved pathways.

Methods {#sec2}
=======

Animals {#sec2-1}
-------

Six healthy adult male Labrador dogs aged 18--24 months with an approximate weight of 25 kg were used in the study. All animals were obtained from the Ninth People's Hospital Animal Center (Shanghai, China). During the experiments, the six dogs were housed separately in kennels with 100% fresh air, an ambient temperature of 25 ± 0.1°C and humidity of 40--70%. They were fed a soft diet once daily and given free access to fresh water. All experiments in the present study were performed in accordance with an ethical permit approved by the Animal Care and Experiment Committee of the Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine, China.

Experimental peri-implantitis {#sec2-2}
-----------------------------

The experimental design is presented in [Figure 1](#F1){ref-type="fig"}A. First, the bilateral mandibular fourth premolar and first molar (P4-M1) were extracted from the six dogs. Three months later, 24 (2 per side for each dog) standard ITI implants (Straumann AG, Waldenburg, Switzerland) were inserted by one experienced operator, according to the manufacturer's recommended protocols. All implants were transmucosal and healing caps were placed. Afterward, tissue flaps were restored, and soft tissues were sutured around each implant using resorbable sutures. All surgeries were performed under general anesthesia with ketamine (10 mg/kg).

![Experimental peri-implantitis\
(**A**) Outline of the animal experiment. (**B**) Clinical photographs: (**a**) implant installment; (**b**) 2 months after ligament placement. (**C**) Representative X-ray image of the implant before and after ligature placement. (**D**) Clinical parameters examined 2 months after the induction of inflammation, \* represents *P*\<0.05.](bsr-37-bsr20170768-g1){#F1}

Buprenorphine HCl was administered post-operatively to all animals to relieve any pain or discomfort, and amoxicillin was used to prevent infection. The animals were allowed to move freely, were fed a soft diet, and were routinely monitored for swelling, dehiscence, and infection. Before ligature placement, plaque control was performed twice weekly using chlorhexidine and gauze.

Three months following implant insertion, peri-implantitis was induced by placing cotton floss ligatures around the implant neck, as previously described \[[@B19]\]. Ligatures must be closely monitored to avoid position shifts or loss. In addition, oral hygiene care was stopped after ligature insertion. The ligatures were then withdrawn 2 months after placement ([Figure 1](#F1){ref-type="fig"}B).

Radiographic measurements ([Figure 1](#F1){ref-type="fig"}C) and clinical examinations ([Figure 1](#F1){ref-type="fig"}D) were performed before ligature placement and 2, 4, 6, and 8 weeks after inflammation induction to evaluate the successful establishment of the animal model. The clinical parameters examined included the clinical attachment level (CAL), gingival index (GI), and bleeding index (BI). Data were recorded from the buccal, medial, distal, and lingual sides of each implant.

Sample collection and RNA isolation {#sec2-3}
-----------------------------------

In the present study, gingival tissues were collected from both healthy and peri-implantitis sites in all the animal subjects and were immediately frozen in liquid nitrogen. Total RNA was extracted with TRIzol (Invitrogen). The RNA concentration and purity were determined by measuring the A260/A280 ratios using the NanoDrop ND-1000 (Agilent Technologies Inc., Wilmington, DE, U.S.A.). RNA samples were immediately frozen and stored at −80°C prior to use.

Analysis of miRNA sequences {#sec2-4}
---------------------------

The total RNA from each sample was used to prepare an miRNA sequencing library for that sample. This preparation process included the following steps: (i) 3′ adaptor ligation, (ii) 5′ adaptor ligation, (iii) cDNA synthesis, (iv) PCR amplification, and (v) the size-specific selection of approximately 150-bp PCR amplicons (corresponding to approximately 22-nt miRNAs). Next, the quality of each sequencing library was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Wilmington, DE, U.S.A.) and the Agilent DNA 1000 chip kit (Agilent, part \# 5067-1504). The libraries were adjusted to 10 nM before cluster generation. The samples were then denatured into ssDNA molecules, captured on Illumina flow cells, amplified *in situ* as clusters and finally sequenced for 36 cycles on an Illumina HiSeq sequencer (Illumina), according to the manufacturer's instructions.

Single-end reads (raw reads) were harvested from the Illumina HiSeq sequencer after quality filtering. The adaptor sequences were trimmed using cutadapt software, resulting in adaptor-trimmed reads (≥15 nts). Next, the trimmed reads from all the samples were pooled and miRDeep2 software was used to predict novel miRNAs. The trimmed reads were aligned to merged pre-miRNA databases (known pre-miRNAs from miRBase plus the newly predicted pre-miRNAs) using NovoAlign software (v2.07.11), with at the most one mismatch. The number of mature miRNA-mapped tags was defined as the raw expression levels of a particular miRNA. The read counts were normalized using the tags per million approach (TPM; namely, the tag counts per million aligned miRNAs). All miRNAs with a fold-change in expression ≥1.5 or ≤ −1.5 and a *P*-value ≤0.05 were considered differentially expressed.

Validation of sequencing results by quantitative real-time PCR {#sec2-5}
--------------------------------------------------------------

The expression levels of selected miRNAs were confirmed by quantitative real-time PCR (qRT-PCR). Briefly, the purified total RNA was reverse transcribed into cDNAs using the TaqMan MicroRNA Reverse Transcription Kit and small RNA-specific RT primers. The reactions were then incubated at 16°C for 30 min, 42°C for 30 min, and 85°C for 5 min and chilled on ice for 5 min, after which the cDNA was stored at −20°C. The qRT-PCR was performed in 20 µl reaction mixtures using the TaqMan Small RNA Assay (Applied Biosystems, Carlsbad, U.S.A.), according to the manufacturer's instructions. U6 was used as an endogenous control to normalize the *C*~t~ values obtained for each gene. The relative expression of a miRNA compared with U6 was calculated using the 2^−ΔΔ*C*^~t~ method.

Target prediction and functional analysis {#sec2-6}
-----------------------------------------

The targets of the differentially expressed miRNAs were predicted using two different target prediction tools: TargetScan (<http://www.targetscan.org/>) and miRanda (<http://www.microrna.org/microrna/home.do>). The intersection of the two datasets was assayed based on the predicted results. To determine the potential biological functions and pathways, the top 100 targets of all differentially expressed miRNAs were further determined and subjected to Gene Ontology (GO) (<http://www.geneontology.org/>) and KEGG (<http://www.genome.jp/kegg/>) pathway analyses. The target function analysis mainly focussed on biological functions, namely, the classification of 'Biological Processes'. Fisher's exact test was used to calculate *P*-values. The false discovery rate (FDR) was calculated to correct the *P*-values using the Benjamini--Hochberg approach.

Statistical analysis {#sec2-7}
--------------------

Numerical data are presented as means ± S.D. The difference between means was analyzed with one-way ANOVA. Differences were considered significant when *P*\<0.05. All statistical analyses were performed with the software SPSS19.0 (SPSS Inc., Chicago, IL, U.S.A.).

Results {#sec3}
=======

Identification of differentially expressed miRNAs in canine peri-implantitis {#sec3-1}
----------------------------------------------------------------------------

To investigate miRNA expression in peri-implantitis, we performed miRNA sequencing using gingival tissues obtained from a canine peri-implantitis model. Based on the criteria described above (*P*\<0.01 and a fold-change in expression ≥1.5 or ≤ −1.5), a total of 38 miRNAs were found to be differentially expressed ([Table 1](#T1){ref-type="table"}). Of these miRNAs, 8 were overexpressed in the diseased tissue compared with healthy tissue, and 30 were underexpressed.

###### List of the top differentially expressed miRNAs between diseased and healthy gingival tissues (*P*\<0.01)

  miRNAs                                                                                       Mature sequence           Fold-change   Regulation
  -------------------------------------------------------------------------------------------- ------------------------- ------------- ------------
  \(A\) Top eight miRNAs with increased expression in diseased compared with healthy gingiva                                           
  cfa-*miR-452*                                                                                AACUGUUUGCAGAGGAAACUGA    2.52          Up
  cfa-*miR-375*                                                                                UUUGUUCGUUCGGCUCGCGUGA    2.43          Up
  cfa-*miR-98*                                                                                 UGAGGUAGUAAGUUGUAUUGUU    2.38          Up
  cfa-*miR-145*                                                                                GUCCAGUUUUCCCAGGAAUCCCU   1.96          Up
  cfa-let-7e                                                                                   UGAGGUAGGAGGUUGUAUAGUU    1.71          Up
  cfa-*miR-142*                                                                                CCCAUAAAGUAGAAAGCACUA     1.71          Up
  cfa-*miR-500*                                                                                AUGCACCUGGGCAAGGAUUCU     1.70          Up
  cfa-*miR-7*                                                                                  UGGAAGACUAGUGAUUUUGUUGU   1.68          Up
  \(B\) Top 30 miRNAs with decreased expression in diseased compared with healthy gingiva                                              
  cfa-let-7g                                                                                   UGAGGUAGUAGUUUGUACAGUU    −1.51         Down
  cfa-*miR-486*                                                                                UCCUGUACUGAGCUGCCCCGA     −1.51         Down
  cfa-*miR-152*                                                                                UCAGUGCAUGACAGAACUUGG     −1.51         Down
  cfa-*miR-127*                                                                                UCGGAUCCGUCUGAGCUUGGCU    −1.55         Down
  cfa-*miR-1271*                                                                               CUUGGCACCUAGUAAGCACU      −1.56         Down
  cfa-*miR-101*                                                                                UACAGUACUGUGAUAACUGA      −1.57         Down
  cfa-*miR-16*                                                                                 UAGCAGCACGUAAAUAUUGGCG    −1.61         Down
  cfa-*miR-200a*                                                                               CAUCUUACCGGACAGUGCUGGA    −1.61         Down
  cfa-*miR-140*                                                                                ACCACAGGGUAGAACCACGGA     −1.67         Down
  cfa-*miR-27b*                                                                                UUCACAGUGGCUAAGUUCUGC     −1.69         Down
  cfa-*miR-146a*                                                                               UGAGAACUGAAUUCCAUGGGUU    −1.74         Down
  cfa-*miR-204*                                                                                UUCCCUUUGUCAUCCUAUGCCU    −1.80         Down
  cfa-*miR-29a*                                                                                UAGCACCAUCUGAAAUCGGUUA    −1.81         Down
  cfa-*miR-26a*                                                                                UUCAAGUAAUCCAGGAUAGGCU    −1.83         Down
  cfa-*miR-451*                                                                                AAACCGUUACCAUUACUGAGUU    −1.89         Down
  cfa-*miR-125a*                                                                               UCCCUGAGACCCUUUAACCUGU    −1.92         Down
  cfa-*miR-93*                                                                                 CAAAGUGCUGUUCGUGCAGGUAG   −1.96         Down
  cfa-*miR-361*                                                                                UUAUCAGAAUCUCCAGGGGUAC    −1.97         Down
  cfa-*miR-27a*                                                                                UUCACAGUGGCUAAGUUCCG      −2.03         Down
  cfa-*miR-532*                                                                                CAUGCCUUGAGUGUAGGACCGU    −2.09         Down
  cfa-let-7c                                                                                   UGAGGUAGUAGGUUGUAUGGUU    −2.11         Down
  cfa-*miR-23a*                                                                                AUCACAUUGCCAGGGAUUU       −2.33         Down
  cfa-*miR-211*                                                                                UUCCCUUUGUCAUCCUUUGCCU    −2.35         Down
  cfa-*miR-92b*                                                                                UAUUGCACUCGUCCCGGCCUCC    −2.40         Down
  cfa-*miR-342*                                                                                UCUCACACAGAAAUCGCACCCGU   −2.58         Down
  cfa-*miR-340*                                                                                UUAUAAAGCAAUGAGACUGAUU    −3.04         Down
  cfa-*miR-374a*                                                                               UUAUAAUACAACCUGAUAAGU     −3.09         Down
  cfa-*miR-9*                                                                                  UCUUUGGUUAUCUAGCUGUAUGA   −4.22         Down
  cfa-*miR-429*                                                                                UAAUACUGUCUGGUAAUGCCGU    −5.58         Down
  cfa-*miR-20a*                                                                                UAAAGUGCUUAUAGUGCAGGUAG   −7.52         Down

According to several previous reports, most of the low-abundance miRNAs function in inflammatory processes, including bone resorption (*miR-26a, miR-27a, miR-101*, and *miR-20a*), periodontal ligament development and mineralization (*miR-101*), inflammatory cytokine secretion (*miR-27a, miR-93, miR-451, let-7c, miR-146a*, and *miR-20a*) and endothelial dysfunction (let-7g). However, as mentioned above, although the absolute number of significantly differentially expressed low-abundance miRNAs was high, certain miRNAs were expressed at increased levels in peri-implantitis. Interestingly, nearly all the high-abundance miRNAs are known to be strongly associated with processes related to the inflammatory response and bone metabolism, such as osteoclast activity (*miR-142, miR-145, miR-375*, and let-7e), inflammation-related signaling (*miR-98*), apoptosis (*miR-142*), tissue fibrogenesis (*miR-142*), and the regulation of endothelial cells (let-7e). Thus, the differentially expressed miRNAs may be associated with the pathology of peri-implantitis.

Confirmation of differentially expressed miRNAs by qRT-PCR {#sec3-2}
----------------------------------------------------------

To confirm the findings obtained by analyzing the miRNA profile, we selected five miRNAs (let-7g, *miR-27a, miR-29a, miR-142*, and *miR-145*) and measured their expression using qRT-PCR ([Figure 2](#F2){ref-type="fig"}). The chosen miRNAs were broadly conserved and related to inflammation and included both miRNAs with relatively increased expression and miRNAs with decreased expression, as reflected by the fold-change in expression. With the exception of *miR-142*, the results for all miRNAs examined using the quantitative assay were consistent with the data obtained from the miRNA sequence analysis, further confirming that these miRNAs may participate in peri-implant infection and validating the accuracy of the sequencing approach. Amongst the four miRNAs, let-7g, *miR-27a*, and *miR-145* were significantly differentially expressed between inflamed tissues and healthy control tissues (*P*\<0.05).

![Validation of sequencing data by qRT-PCR\
Fold-changes in the expression of three down-regulated miRNAs (let-7g, *miR-27a*, and *miR-29a*) and two up-regulated miRNAs (*miR-142* and *miR-145*) were verified. \*, statistically significant difference between the peri-implantitis and control groups, *P*\<0.05.](bsr-37-bsr20170768-g2){#F2}

Target prediction and functional annotations {#sec3-3}
--------------------------------------------

In general, only a fraction of predicted targets have been confirmed to be regulated by a given miRNA in a specific tissue \[[@B20]\]. Therefore, only the top 100 target genes (results not shown) from overlapping results obtained using two well-established prediction tools, TargetScan and miRanda, amongst all differentially expressed miRNAs were retained and considered for further functional annotation analysis to increase the likelihood of predicting genuine miRNA targets.

To clearly interpret the role of the miRNAs in changes in disease development in either direction, we next performed GO and KEGG analyses for up-regulated genes (targets of the low-abundance miRNAs) and down-regulated genes (targets of the high-abundance miRNAs), respectively. GO terms with *P*\<0.001 and FDR ≤25% were considered statistically significant. Regarding the biological functions associated with the predicted targets, the up-regulated genes represented 75 GO terms, amongst which regulation of macromolecule biosynthetic processes, cell adhesion, phosphorylation, angiogenesis, and the mitogen-activated protein kinase (MAPK) cascade, amongst other terms, were all correlated with active inflammation. The GO term of regulation of macromolecule biosynthetic processes has been described to be associated with macrophage differentiation \[[@B21],[@B22]\], which is closely related to osteoclast precursor development \[[@B23]\]. Furthermore, the regulation of biosynthetic processes, regulation of cellular metabolic processes, and regulation of nucleobase-containing compound metabolic processes ranked as the top three over-represented GO terms and regulation of cellular metabolic process was associated with the greatest number of genes ([Figure 3](#F3){ref-type="fig"}A). Correspondingly, nucleic acid metabolic processes, cellular aromatic compound metabolic processes, and nucleobase-containing compound metabolic processes were prominent amongst the enriched GO terms for down-regulated genes ([Figure 3](#F3){ref-type="fig"}B).

![Functional annotations of target genes\
Biological process categories of target genes of low-abundance miRNAs (**A**) and high-abundance miRNAs (**B**) in the GO analysis. The numbers shown in each section of the pie chart represent the number of putative target genes mapped to the corresponding GO terms. Bar graphs show the −log10 (*P*-value) of each GO term.](bsr-37-bsr20170768-g3){#F3}

Regarding the pathway analysis, 14 and 38 statistically significant (*P*\<0.05) terms were identified for down-regulated genes and up-regulated genes, respectively ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Amongst the pathways for up-regulated genes, the MAPK signaling pathway ([Figure 4](#F4){ref-type="fig"}), the NF-κB signaling pathway (Supplementary Figure S1) and the toll-like receptor signaling pathway (Supplementary Figure S2) were highly enriched in the KEGG analysis. Other pathways that are closely correlated with inflammation regulation and osteoclast activity were also statistically significant, such as the PI3K-Akt signaling pathway, the TNF signaling pathway and the TGF-β signaling pathway, indicating that miRNAs mediate the inflammatory process through their effects on intricate signaling pathways. In contrast, the KEGG pathway evaluation of down-regulated genes in peri-implantitis lesions revealed that the genes were mostly implicated in the following pathways, amongst others: phagosomes, adherens junctions, thyroid hormone signaling, and lysosomes. Phagosomes and lysosomes are both related to the digestion and removal of bacteria.

![The KEGG analysis annotated the MAPK signaling pathway as significantly enriched in peri-implantitis\
Yellow nodes represent up-regulated genes enriched in peri-implantitis.](bsr-37-bsr20170768-g4){#F4}

###### Enriched KEGG pathways involving target genes of 30 low-abundance miRNAs (*P*\<0.05)

  Pathway ID   Definition                                                 Hits   Total   Percent (%)   Fisher-P value
  ------------ ---------------------------------------------------------- ------ ------- ------------- ----------------
  cfa05206     MiRNAs in cancer                                           31     139     22.30%        2.70E-05
  cfa05200     Pathways in cancer                                         62     393     15.78%        4.29E-04
  cfa04010     MAPK signaling pathway                                     43     252     17.06%        6.55E-04
  cfa04060     Cytokine--cytokine receptor interaction                    38     216     17.59%        7.35E-04
  cfa04151     PI3K-Akt signaling pathway                                 53     334     15.87%        9.73E-04
  cfa03060     Protein export                                             8      23      34.78%        1.55E-03
  cfa04933     AGE-RAGE signaling pathway in diabetic complications       21     102     20.59%        1.57E-03
  cfa04510     Focal adhesion                                             35     204     17.16%        1.84E-03
  cfa04810     Regulation of actin cytoskeleton                           36     212     16.98%        1.92E-03
  cfa04974     Protein digestion and absorption                           18     84      21.43%        2.08E-03
  cfa04062     Chemokine signaling pathway                                30     172     17.44%        2.94E-03
  cfa04722     Neurotrophin signaling pathway                             22     120     18.33%        5.56E-03
  cfa04320     Dorsoventral axis formation                                8      28      28.57%        6.14E-03
  cfa05205     Proteoglycans in cancer                                    32     197     16.24%        6.65E-03
  cfa04666     Fc γ R-mediated phagocytosis                               17     88      19.32%        8.25E-03
  cfa04068     FoxO signaling pathway                                     23     132     17.42%        8.72E-03
  cfa04668     TNF signaling pathway                                      19     105     18.10%        1.10E-02
  cfa04670     Leukocyte transendothelial migration                       21     120     17.50%        1.13E-02
  cfa04360     Axon guidance                                              22     128     17.19%        1.19E-02
  cfa04550     Signaling pathways regulating pluripotency of stem cells   23     138     16.67%        1.47E-02
  cfa05212     Pancreatic cancer                                          13     65      20.00%        1.48E-02
  cfa00310     Lysine degradation                                         11     52      21.15%        1.60E-02
  cfa04115     p53 signaling pathway                                      13     66      19.70%        1.67E-02
  cfa04350     TGF-β signaling pathway                                    15     82      18.29%        2.04E-02
  cfa04512     ECM--receptor interaction                                  15     82      18.29%        2.04E-02
  cfa05222     Small cell lung cancer                                     15     84      17.86%        2.50E-02
  cfa04919     Thyroid hormone signaling pathway                          19     115     16.52%        2.72E-02
  cfa02010     ABC transporters                                           9      43      20.93%        2.99E-02
  cfa05166     HTLV-I infection                                           35     246     14.23%        3.26E-02
  cfa04064     NF-κB signaling pathway                                    15     87      17.24%        3.32E-02
  cfa05202     Transcriptional misregulation in cancer                    24     158     15.19%        3.59E-02
  cfa05220     Chronic myeloid leukemia                                   13     73      17.81%        3.61E-02
  cfa05146     Amoebiasis                                                 16     96      16.67%        3.77E-02
  cfa04917     Prolactin signaling pathway                                13     74      17.57%        3.98E-02
  cfa04144     Endocytosis                                                35     252     13.89%        4.42E-02
  cfa04620     Toll-like receptor signaling pathway                       16     98      16.33%        4.44E-02
  cfa04014     Ras signaling pathway                                      31     220     14.09%        4.74E-02
  cfa00603     Glycosphingolipid biosynthesis -- globo series             4      14      28.57%        4.96E-02

###### Enriched KEGG pathways involving target genes of eight high-abundance miRNAs (*P*\<0.05)

  Pathway ID   Definition                                               Hits   Total   Percent (%)   Fisher-P value
  ------------ -------------------------------------------------------- ------ ------- ------------- ----------------
  cfa04145     Phagosome                                                11     141     7.80%         3.07E-03
  cfa04520     Adherens junction                                        7      73      9.59%         5.73E-03
  cfa04919     Thyroid hormone signaling pathway                        9      115     7.83%         7.04E-03
  cfa04142     Lysosome                                                 9      117     7.69%         7.86E-03
  cfa04320     Dorsoventral axis formation                              4      28      14.29%        8.87E-03
  cfa05412     Arrhythmogenic right ventricular cardiomyopathy (ARVC)   6      72      8.33%         1.97E-02
  cfa05152     Tuberculosis                                             10     164     6.10%         2.40E-02
  cfa04916     Melanogenesis                                            7      100     7.00%         2.89E-02
  cfa05323     Rheumatoid arthritis                                     6      82      7.32%         3.47E-02
  cfa04390     Hippo signaling pathway                                  9      153     5.88%         3.83E-02
  cfa05414     Dilated cardiomyopathy                                   6      85      7.06%         4.03E-02
  cfa00130     Ubiquinone and other terpenoid-quinone biosynthesis      2      11      18.18%        4.05E-02
  cfa03420     Nucleotide excision repair                               4      44      9.09%         4.08E-02

Discussion {#sec4}
==========

Peri-implant infection is initiated by biofilm accumulation around the implant surface. At the initial stage, peri-implant mucositis is established, wherein inflammation culminates in an acanthotic epithelium, connective tissue loss, microvascular changes, and increased infiltration of T and B cells, neutrophils, and macrophages \[[@B24]\]. The swift progression to peri-implantitis is characterized by increased proportions of immune cells and associated inflammatory mediators and a relatively large infiltrate that expands apically to the junctional epithelium toward the bone marrow \[[@B17],[@B25]\]. Hence, peri-implant inflammation appears to be triggered by a set of consecutive events, including an immune response; cell apoptosis, proliferation, and differentiation; and immune cell adhesion and migration. However, although peri-implant infections are well described histopathologically, the molecular events that govern the development of these infections have not yet been completely characterized. Certain studies have attempted to correlate miRNAs with the pathogenesis of peri-implantitis \[[@B26]\]. In particular, it has been noted that *miR-146a* and *miR-499* gene polymorphisms may be genetic determinants of an increased risk of peri-implantitis in Iranians. To date, the present study is the first to examine the expression of miRNAs in peri-implantitis and to provide a foundation for further mechanistic experiments aimed at dissecting the roles of miRNAs in peri-implant tissue homeostasis and pathology.

Because high genetic heterogeneity in the human population may skew experimental results, we established an experimental peri-implantitis model in six similar dogs using the ligature induction method. A very high prevalence of periodontitis has been reported in the canine population, and the histological traits of the diseased periodontium are similar between canines and humans \[[@B27]\]. Moreover, the bone defects observed in ligature-induced peri-implantitis seem to resemble naturally occurring lesions in humans \[[@B28]\]. RNA-Seq, as a very high-throughput quantitative method, is reported to be highly accurate in quantitating gene expression levels and sensitive in quantitating genes expressed at either low or very high levels \[[@B29]\]. Therefore, we employed this method to obtain miRNA expression patterns in peri-implantitis by comparing inflamed peri-implant and healthy gingival tissues.

According to the RNA-Seq analysis, 8 and 30 miRNAs were up-regulated and down-regulated, respectively, using the criteria *P*≤0.01 and a fold-change in expression ≥1.5. These miRNAs are likely to promote disease or to be expressed in an attempt to down-regulate immune activation and bone resorption in peri-implantitis lesions. A well-known example of the former is let-7e, a member of the let-7 family that is evolutionarily conserved from bacteria to humans. Specifically, let-7e acts as a key regulator of bone metabolism and inflammation. For example, let-7e overexpression activates Th1 and Th17 cells and aggravates experimental autoimmune encephalomyelitis and Hashimoto's disease by targetting IL-10 \[[@B30],[@B31]\]. Furthermore, let-7e enhances the inflammatory response in endothelial cells and promotes proper differentiation of monocytes into osteoclasts by stimulating both the nuclear translocation of NF-κB and activation of the NF-κB pathway \[[@B32],[@B33]\]. Immune cells activated by proinflammatory cytokines and adhesion molecules adhere to and migrate through the vessel wall and into inflammatory sites, followed by bone resorption.

Many of the miRNAs identified here are also known to have disease-suppressing functions in periodontitis and other inflammatory diseases. Two examples are *miR-27a* and *miR-146a*, which are expressed at lower levels in diseased tissues. Notably, *miR-27a* functions as a positive regulator of osteogenic differentiation via complex modulatory mechanisms \[[@B34]--[@B36]\]. In addition, *miR-27a* is down-regulated in macrophages following TLR2 and TLR4 stimulation and increases the expression of IL-10, one of the most important anti-inflammatory mediators. Down-regulation of *miR-27a* activates the IL-10-dependent JAK1-STAT3 pathway, likely to be as a result of increased IL-10 expression \[[@B37]\]. Based on these findings, we propose that the *miR-27a* down-regulation identified in the present study may act as a negative regulatory mechanism that prevents overly exuberant TLR2- and TLR4-driven inflammatory responses. In addition, tipping the balance between osteoblasts and osteoclasts toward bone resorption in peri-implantitis may also explain why *miR-27a* is down-regulated. The other miRNA, *miR-146a*, is up-regulated upon TLR activation by LPS or by proinflammatory cytokines such as IL-1β and TNF-α in an NF-κB-dependent manner \[[@B38],[@B39]\]. Both IL-1β and TNF-α are important mediators of the pathogenesis of peri-implantitis \[[@B9]\]. IL-1 receptor associated kinase (IRAK1) and TNF receptor associated factor-6 (TRAF6) are down-regulated by *miR-146a*, thereby producing a negative feedback loop to fine-tune the immune response \[[@B40]\]. In contrast with most reports of *miR-146a* expression in patients with periodontitis \[[@B16],[@B41],[@B42]\], the present study showed low expression of *miR-146a* in inflamed peri-implant tissues. Therefore, we readily understand the high proportions of IL-1β and TNF-α and a more aggressive immune reaction in peri-implantitis compared with periodontitis.

To understand the functional outcome of miRNA dysregulation, we investigated the pathways and functions enriched in the target genes. In addition to processes relevant to cell proliferation and basic metabolism, two of the most enriched functions in the target genes were the regulation of macromolecule biosynthesis processes and nitrogen-containing compound metabolic processes. Macromolecule synthesis is the main housekeeping function of immune cells, and it is required for immune activation \[[@B43]\]; macromolecules are responsible for inducing the expression of proinflammatory cytokines \[[@B44]\]. Cytokines, such as TNF-α, IL-1β, IL-6, and IL-17, have been shown to directly or indirectly promote osteoclast differentiation and function by acting on cells of the osteoclast lineage or other cell types to regulate expression of the key osteoclastogenic factor RANKL and/or its inhibitor, osteoprotegerin (OPG) \[[@B45],[@B46]\]. The metabolic processes for nitrogen-containing compounds mainly involve inducible nitric oxide (NO) synthase (iNOS) and NO. According to previous studies, iNOS induces NO production and is required for *Porphyromonas gingivalis* (Pg) induced alveolar bone loss in periodontal disease. Meanwhile, NO is an important element of the host defense machinery against the periodontal pathogen Pg \[[@B47],[@B48]\]. Collectively, the GO results collected in the current study elucidated the role of the differentially expressed miRNAs in regulating bone destruction and the expression of immune-related genes.

RANKL, a member of the TNF superfamily, is a protein located on the membrane of osteoblasts and their precursors that recognizes its receptor, RANK, on marrow macrophages, prompting them to assume the osteoclast phenotype. Importantly, the function of these cells in osteoclast metabolism has been recognized in peri-implantitis, and RANK may be a pathological determinant of peri-implantitis \[[@B49]\]. TRAF proteins are recruited following RANKL and RANK binding and then regulate the transduction of signals from RANK, with subsequent activation of the NF-κB and MAPK pathways. These two signaling pathways directly regulate the expression of osteoclastic genes, such as *CTSK, MMP-9*, and *TRAP*, which regulate the formation of bone resorption pits during osteoclast differentiation \[[@B50]\]. Interestingly, the pathways described above, particularly the MAPK signaling pathway, are all predominantly enriched in peri-implantitis lesions. As mentioned above, the potential target genes of *miR-146a* include IRAK1 and TRAF6. These two target genes are essential signaling components of IL-1R- and TLR-mediated NF-κB and MAPK activation \[[@B51]--[@B53]\]. Thus, down-regulation of *miR-146a* in peri-implantitis should diminish the inhibition of IRAK1 and TRAF6 and promote activation of the NF-κB and MAPK pathways. However, researchers have not clearly determined whether *miR-146a* down-regulation promotes osteoclast differentiation in peri-implantitis. Thus, future studies are warranted to validate the function and mechanism of *miR-146a* in the osteoclastogenesis of alveolar bone marrow cells.

In the present study, we used an miRNA sequence analysis to identify the miRNAs that were differentially expressed during peri-implantitis. Bioinformatics technology provided insights into the potential biological effects and showed particular enrichment of target genes involved in the MAPK signaling pathway. These findings shed light on the regulatory mechanisms underlying peri-implantitis and may open new avenues for future research into the etiology, mechanism, and treatment of peri-implantitis. The role of certain miRNAs in peri-implantitis is currently being investigated further.

Supporting information {#sec5}
======================



We thank Cloud-Seq Biotech Ltd. Co. (Shanghai, China) for supporting the equipment of high throughput sequencing.

Funding {#sec6}
=======

This work was supported by the National Natural Science Foundation of China \[grant numbers 31470946, 81170988\].

Author contribution {#sec7}
===================

H.H., W.M., and T.W. conceived and designed the experiment. X.C. and X.W. performed the experiments. X.W. and Q.G. analyzed the data. X.W. wrote the manuscript.

Competing interests {#sec8}
===================

The authors declare that there are no competing interests associated with the manuscript.

FDR

:   false discovery rate

GO

:   Gene Ontology

iNOS

:   inducible nitric oxide synthase

IRAK1

:   IL-1 receptor associated kinase

MAPK

:   mitogen-activated protein kinase

NF-κB

:   nuclear factor κB

NO

:   nitric oxide

Pg

:   *Porphyromonas gingivalis*

qRT-PCR

:   quantitative real-time PCR

RANKL

:   receptor activator of NF-κB ligand

TRAF6

:   TNF receptor associated factor-6

TNF-α

:   tumor necrosis factor-α

TGF-β

:   transforming growth factor-β

TLR

:   Toll-like receptor

LPS

:   lipopolysaccharides

CTSK

:   cathepsin K

TRAP

:   tartrate-resistant acid phosphatase

[^1]: These authors contributed equally to this work.
